U.S. stock market midday update: Endra Life Sciences down 8.66%

U.S. Stock Market Midday Update ENDRA Life Sciences fell 8.66%, with increased trading volume. Based on recent key news: On July 24, a block trade occurred in Bio Valley at a price 26.5% lower than the closing price that day, leading to a lack of confidence in the biotechnology sector and affecting ENDRA Life Sciences' stock price decline. On July 17, the Hong Kong pharmaceutical sector surged, but ENDRA failed to benefit and was pressured as market funds flowed to other popular stocks. On July 27, trading volume for small-cap stocks in the U.S. soared, and as one of the small-cap stocks, ENDRA was affected by market volatility, causing its stock price to drop. Stocks with High Trading Volume in the Industry Intuitive Surgical rose 0.91%, with increased trading volume. Based on recent important news: On July 29, Intuitive Surgical faced competitive threats; despite its good business condition, market concerns about its profit model led to stock price fluctuations. On July 30, the board's executive chairman Gary S. Guthart sold company common stock, drawing market attention and causing stock price volatility. On July 27, analysts did not include Intuitive Surgical in their recommended buy list, affecting market confidence. Abbott rose 0.73%, with increased trading volume. Based on recent key news: On July 29, Abbott planned to significantly increase stock buybacks after a strong second quarter, driving the stock price up. On July 29, market analysts rated Abbott as "moderate buy," but noted better investment options, affecting market sentiment. On July 28, Abbott's quarterly earnings report showed actual earnings below expectations, although overall performance was strong, putting short-term pressure on the stock price. Boston Scientific rose 0.82%, with increased trading volume. Based on recent important news: On July 28, Boston Scientific director Edward J. Ludwig sold company common stock, drawing market attention and causing stock price volatility. On July 23, Boston Scientific released its second-quarter earnings report, with revenue reaching $5.06 billion, exceeding analyst expectations and driving the stock price up. Recently, Boston Scientific made progress in regulatory victories and manufacturing optimization, enhancing market confidence. Stocks with High Market Capitalization in the Industry Stryker fell 0.29%, with increased trading volume. Based on recent important news: On July 28, TD Cowen analyst Josh Jennings maintained a buy rating on Stryker with a target price of $435, based on the company's recent strong performance, stabilizing the stock price. On July 27, retail investors in the U.S. surged, with small-cap trading volume soaring, increasing market volatility. On July 27, Intel's poor earnings report caused its stock price to plummet 8.53%, affecting the overall sentiment in the technology sector